-
1.发明申请COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE 有权用于治疗自身免疫疾病的BLYS抑制剂和抗CD 20剂的组合公开(公告)号：US20090148442A1
公开(公告)日：2009-06-11
申请号：US12252955
申请日：2008-10-16
IPC分类号： A61K39/395 , A61K38/16 , A61P37/02
CPC分类号： A61K39/3955 , A61K38/1709 , A61K38/1793 , A61K39/395 , A61K39/39541 , A61K45/06 , A61K2300/00
摘要： The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF—R-Fc-fusion protein comprising the extracellular domain of BAFF—R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
摘要翻译： 本发明涉及涉及BLyS或BLyS / APRIL抑制的新型联合疗法和用于治疗自身免疫性疾病的抗CD20剂。 一种优选的方法是其中BLyS拮抗剂是Fc-融合蛋白，其可以是包含TACI的胞外结构域或其功能片段的TACI-Fc-融合蛋白，包含细胞外结构域的BAFF-R-Fc-融合蛋白 BAFF-R或其功能片段，或包含BCMA细胞外结构域的BCMA-Fc-融合蛋白或其功能片段。 在本发明的方法中，考虑的一些抗CD20药物包括RITUXAN，ocrelizumab，奥美单抗（HuMax-CD20），TRU-015和DXL625，尽管与CD20结合的任何试剂可能是合适的 。 本发明的方法降低了需要这种还原的患者中的B细胞的水平，例如患有自身免疫性疾病的患者。
-
2.发明授权Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease 有权BLyS抑制和抗CD 20药物联合用于治疗自身免疫性疾病公开(公告)号：US08956611B2
公开(公告)日：2015-02-17
申请号：US12252955
申请日：2008-10-16
IPC分类号： A61K39/395 , A61K45/06 , A61K38/17
CPC分类号： A61K39/3955 , A61K38/1709 , A61K38/1793 , A61K39/395 , A61K39/39541 , A61K45/06 , A61K2300/00
摘要： The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF—R-Fc-fusion protein comprising the extracellular domain of BAFF—R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, (rituximab),ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
摘要翻译： 本发明涉及涉及BLyS或BLyS / APRIL抑制的新型联合疗法和用于治疗自身免疫性疾病的抗CD20剂。 一种优选的方法是其中BLyS拮抗剂是Fc-融合蛋白，其可以是包含TACI的胞外结构域或其功能片段的TACI-Fc-融合蛋白，包含细胞外结构域的BAFF-R-Fc-融合蛋白 BAFF-R或其功能片段，或包含BCMA细胞外结构域的BCMA-Fc-融合蛋白或其功能片段。 在本发明的方法中，考虑的一些抗CD20药物包括RITUXAN，（利妥昔单抗），ocrelizumab，奥美珠单抗（HuMax-CD20），TRU-015和DXL625，尽管与CD20结合的任何试剂可能是合适的 。 本发明的方法降低了需要这种还原的患者中的B细胞的水平，例如患有自身免疫性疾病的患者。
-
搜索结果
2 条记录 (耗时 0.012 秒)
